PureTech launches phase II ‘long COVID’ drug trial
LYT-100 will be evaluated in patients with persistent symptoms caused by COVID-19
Read More
Tag: PureTech
PureTech advances experimental COVID-19 drug into global trials
LYT-100 employs a multimodal mechanism of action to potentially reduce, delay or prevent the lung dysfunction documented in COVID-19 patients
Read More
First patient dosed in potential lymphoedema treatment trial
The drug being evaluated is an oral, small molecule drug candidate known as deupirfenidone.
Read More
PureTech acquires LYT-100 to treat lymphedema
The candidate, LYT-100, demonstrated anti-fibrotic and anti-inflammatory mechanisms in pre-clinical studies.
Read More
PureTech affiliate Karuna advances schizophrenia candidate
Karuna Pharmaceuticals, an affiliate of UK-listed biopharma PureTech Health, has kicked off a Phase II study of KarXT, which is being developed for the treatment of psychosis in schizophrenia.
Read More
PureTech lifted by news of Roche deal
Shares in UK-based clinical-stage biopharm PureTech Health have been given a boost by news that Roche has signed up to advance its exosome platform technology in a deal potentially worth more than $1 billion.
Read More
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
